Who are tolterodine , mirabegron's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tolterodine-mirabegron.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

tolterodine , mirabegron — Competitive Intelligence Brief

tolterodine , mirabegron (tolterodine , mirabegron) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimuscarinic and beta-3 adrenergic agonist combination. Area: Urology.

marketed Antimuscarinic and beta-3 adrenergic agonist combination Muscarinic M3 receptor and beta-3 adrenergic receptor Urology Small molecule Live · refreshed every 30 min

Target snapshot

tolterodine , mirabegron (tolterodine , mirabegron) — Far Eastern Memorial Hospital. Tolterodine and mirabegron work together to reduce overactive bladder symptoms through complementary pathways: tolterodine blocks muscarinic receptors to decrease bladder contractions, while mirabegron activates beta-3 adrenergic receptors to relax the detrusor muscle.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
tolterodine , mirabegron TARGET	tolterodine , mirabegron	Far Eastern Memorial Hospital	marketed	Antimuscarinic and beta-3 adrenergic agonist combination	Muscarinic M3 receptor and beta-3 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimuscarinic and beta-3 adrenergic agonist combination class)

Far Eastern Memorial Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). tolterodine , mirabegron — Competitive Intelligence Brief. https://druglandscape.com/ci/tolterodine-mirabegron. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab